Spatial intra‐tumour heterogeneity in acquired resistance to targeted therapy complicates the use of PDX models for co‐clinical cancer studies
Abstract Targeted therapy in the treatment of cancer has produced great clinical successes. However, with these came the challenge of acquired resistance. Melanoma, a cancer that carries one of the highest mutational burdens, displays great complexity in mutational acquired resistance with a notable...
Saved in:
| Main Author: | Claudia Wellbrock |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2015-07-01
|
| Series: | EMBO Molecular Medicine |
| Online Access: | https://doi.org/10.15252/emmm.201505431 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Phylogenetic quantification of intra-tumour heterogeneity.
by: Roland F Schwarz, et al.
Published: (2014-04-01) -
Spatial genomics uncovers cytokines promoting ovarian tumour heterogeneity and immunotherapy resistance
by: Gurkan Mollaoglu, et al.
Published: (2025-02-01) -
Investigating resistance to 5-Azacytidine and Venetoclax in PDX models of MDS/AML
by: Petra Bašová, et al.
Published: (2025-01-01) -
Intratumoral heterogeneity drives acquired therapy resistance in a patient with metastatic prostate cancer
by: Dena P. Rhinehart, et al.
Published: (2024-12-01) -
Investigating intra‐tumoural heterogeneity and microenvironment diversity in primary cardiac angiosarcoma through single‐cell RNA sequencing
by: Jingyuan Huo, et al.
Published: (2024-12-01)